CL2019001105A1 - Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño. - Google Patents

Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño.

Info

Publication number
CL2019001105A1
CL2019001105A1 CL2019001105A CL2019001105A CL2019001105A1 CL 2019001105 A1 CL2019001105 A1 CL 2019001105A1 CL 2019001105 A CL2019001105 A CL 2019001105A CL 2019001105 A CL2019001105 A CL 2019001105A CL 2019001105 A1 CL2019001105 A1 CL 2019001105A1
Authority
CL
Chile
Prior art keywords
compounds
disorders
procedure
obtaining
pharmaceutical composition
Prior art date
Application number
CL2019001105A
Other languages
English (en)
Spanish (es)
Inventor
Werneck Guimarães Cristiano Ruch
Zaneti De Azevedo Hatylas Felype
Alessandra Mascarello
Da Costa Renata Watanabe
Torres Russo Valter Freire
De Souza Russo Elisa Mannochio
Original Assignee
Ache Laboratorios Farmaceuticos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos Sa filed Critical Ache Laboratorios Farmaceuticos Sa
Publication of CL2019001105A1 publication Critical patent/CL2019001105A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2019001105A 2016-10-24 2019-04-23 Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño. CL2019001105A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102016024814A BR102016024814A2 (pt) 2016-10-24 2016-10-24 composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono

Publications (1)

Publication Number Publication Date
CL2019001105A1 true CL2019001105A1 (es) 2019-09-06

Family

ID=62023150

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001105A CL2019001105A1 (es) 2016-10-24 2019-04-23 Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño.

Country Status (20)

Country Link
US (2) US10781182B2 (https=)
EP (2) EP3529234B1 (https=)
JP (1) JP7194683B2 (https=)
KR (1) KR102594251B1 (https=)
CN (2) CN115181108A (https=)
AR (1) AR109467A1 (https=)
AU (1) AU2017351756B2 (https=)
BR (1) BR102016024814A2 (https=)
CL (1) CL2019001105A1 (https=)
CO (1) CO2019004756A2 (https=)
DK (1) DK3529234T3 (https=)
EC (1) ECSP19032963A (https=)
ES (2) ES2970546T3 (https=)
FI (1) FI3529234T3 (https=)
MX (1) MX392990B (https=)
PE (2) PE20250558A1 (https=)
PT (1) PT3529234T (https=)
SG (2) SG10202009001TA (https=)
UY (2) UY37334A (https=)
WO (1) WO2018076090A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
EP3640251B1 (en) 2016-10-24 2021-12-08 Astrazeneca AB 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
PL3494116T3 (pl) 2017-01-30 2020-04-30 Astrazeneca Ab Modulatory receptora estrogenowego
AR121842A1 (es) * 2020-04-15 2022-07-13 Ache Laboratorios Farmaceuticos Sa Compuesto de benzimidazol para el tratamiento de trastornos metabólicos
MX2022013391A (es) 2020-04-24 2022-11-30 Astrazeneca Ab Pauta posologica para el tratamiento del cancer.
MX2022013258A (es) 2020-04-24 2022-11-14 Astrazeneca Ab Formulaciones farmaceuticas.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5260051A (en) 1990-12-17 1993-11-09 Lever Brothers Company, Division Of Conopco, Inc. Compositions comprising phosphate ester compounds containing a beneficial reagent component
FR2674524B1 (fr) 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
JP3559045B2 (ja) * 1994-06-10 2004-08-25 ナウチノ−イススレドバテルスキ インスティテュト ファルマコロギイ ロスシイスコイ アカデミイ メディツィンスキフ ナウク 薬理学的活性を有する2−メルカプトベンズイミダゾール誘導体
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
FR2738818B1 (fr) 1995-09-18 1997-12-05 Valentonine Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
RU2190609C2 (ru) 1996-12-10 2002-10-10 Бристол-Маерс Сквибб Компани Производные бензодиоксола, бензофурана, дигидробензофурана и бензодиоксана и содержащие их композиции
US6214869B1 (en) 1998-06-05 2001-04-10 Bristol-Myers Squibb Heterocyclic cis cyclopropane derivatives as melatonergic agents
DE60007745T2 (de) 1999-06-30 2005-03-10 Bristol-Myers Squibb Co. Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe
US7408067B2 (en) 2002-01-17 2008-08-05 Merck + Co., Inc. Aza-cyclic compounds as modulators of acetylcholine receptors
CN1922141A (zh) * 2004-02-23 2007-02-28 大日本住友制药株式会社 新的杂环化合物
ES2264641B1 (es) * 2005-06-17 2008-03-01 Quimica Sintetica, S.A. Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.
US20090298811A1 (en) * 2006-09-12 2009-12-03 Pfizer Inc Benzimidazolone derivatives
US20100056515A1 (en) * 2006-10-25 2010-03-04 Kazuyoshi Aso Benzimidazole compounds
RU2401831C2 (ru) * 2008-12-15 2010-10-20 Алла Хем, Ллс Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono

Also Published As

Publication number Publication date
AR109467A1 (es) 2018-12-12
EP3741760C0 (en) 2024-12-04
DK3529234T3 (da) 2024-02-05
SG11201903113TA (en) 2019-05-30
EP3529234A4 (en) 2020-03-11
CN110088092B (zh) 2022-10-04
JP7194683B2 (ja) 2022-12-22
JP2019537624A (ja) 2019-12-26
US11091445B2 (en) 2021-08-17
CO2019004756A2 (es) 2019-05-21
BR112019008197A2 (pt) 2019-07-16
CN115181108A (zh) 2022-10-14
MX392990B (es) 2025-03-24
PT3529234T (pt) 2024-02-01
BR102016024814A2 (pt) 2018-05-08
PE20250558A1 (es) 2025-02-24
US10781182B2 (en) 2020-09-22
SG10202009001TA (en) 2020-10-29
CN110088092A (zh) 2019-08-02
ES3013994T3 (en) 2025-04-16
US20190270711A1 (en) 2019-09-05
EP3741760A1 (en) 2020-11-25
PE20191046A1 (es) 2019-08-06
US20200277265A1 (en) 2020-09-03
ES2970546T3 (es) 2024-05-29
UY40644A (es) 2024-02-29
CA3042040A1 (en) 2018-05-03
EP3529234B1 (en) 2023-11-29
MX2019004782A (es) 2019-10-09
FI3529234T3 (fi) 2023-12-28
AU2017351756B2 (en) 2022-01-27
AU2017351756A1 (en) 2019-05-09
KR20190066023A (ko) 2019-06-12
ECSP19032963A (es) 2019-05-31
EP3741760B1 (en) 2024-12-04
UY37334A (es) 2018-04-30
EP3529234A1 (en) 2019-08-28
WO2018076090A1 (en) 2018-05-03
KR102594251B1 (ko) 2023-10-25

Similar Documents

Publication Publication Date Title
CL2019001105A1 (es) Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño.
EA202190196A1 (ru) Новые гетероциклические производные, применимые в качестве ингибиторов shp2
MX388749B (es) Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak.
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
CO6870032A2 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
MX2013006634A (es) Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1.
CO6361937A2 (es) Derivados de heteroaril amidas y sus usos como activadores de glucoquinasa
CY1121898T1 (el) Ενωσεις αμιδιου ως αγωνιστες tου υποδοχεα 5-ht4
EA201790626A1 (ru) Макроциклические ингибиторы lrrk2-киназы
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
MX2019007161A (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CO6491034A2 (es) Derivados de amida espirocíclicos
CO2019002517A2 (es) Inhibidores de dopamina–β–hidroxilasa
CY1125323T1 (el) ΚΥΚΛΙΚΑ ΠΑΡΑΓΩΓΑ ΑΙΘΕΡΑ ΤΟΥ ΠΥΡΑΖOΛO[1,5- a]ΠΥΡΙΜΙΔΙΝO-3-ΚΑΡΒOΞΥΑΜΙΔΙOΥ
EA201000675A1 (ru) Производные хромана как модуляторы trpv3
EA201990362A1 (ru) Аналог вортиоксетина и его применение и получение
EA201991395A1 (ru) Новые композиции для лечения суставных нарушений
MX2019000982A (es) Compuestos y composiciones y usos de los mismos.
MX2018012840A (es) Compuestos heterociclicos biciclicos sustituidos.
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
EA201890769A1 (ru) Производные 2,3,4,5-тетрагидропиридин-6-амина
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
CU20180044A7 (es) Derivados novedosos de diamino piridina